{"disease":{"id":"hattr-amyloidosis","name":"hattr amyloidosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03728634","title":"Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05040373","title":"Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}